Contact Us

EpiMedTech Global Validates Unique epiCervix HPV Combo Test for Cervical Cancer Detection

EpiMedTech Global official press release logo with 'Harnessing the epigenome' tagline, highlighting biotechnology innovation
Singapore, November 18 2024 — EpiMedTech Global Singapore is thrilled to announce the successful validation of our groundbreaking Epicervix HPV combo test, now certified for CLIA and CAP. This innovative test utilizes next-generation sequencing (NGS) technology, setting a new standard for cervical cancer detection and health monitoring.

The epiCervix test integrates HPV testing with advanced DNA methylation-based cancer detection, providing a comprehensive assessment of cervical health. It detects the presence of cancer DNA in cervical samples, delivering a highly accurate quantification of methylated and unmethylated copies across four key genes. These genes are typically methylated in cervical cancer and remain unmethylated in non-cancerous samples.

Traditionally, Pap smears have focused on identifying abnormal cells within the cervix. However, our test enhances sensitivity through the molecular detection of cancer DNA, successfully identifying cancer DNA in early premalignant lesions.

We are proud to advance our capabilities by incorporating next-generation sequencing-based human papillomavirus (HPV) testing in cervical biopsies. The advantage of our HPV assay over conventional PCR-based tests lies in its ability to provide specific information on HPV strains.

The epiCervix cancer detection test has been rigorously validated in studies conducted at the Department of Oncology at McGill University, with results published in the International Journal of Cancer.

Leave a Comment

Your email address will not be published. Required fields are marked *

Recent Press Releases

Address

EpiMedTechGlobal (EMTG)
60 Paya Lebar Road, #08-06 Paya Lebar Square
Singapore 409051

Honk Kong Lab
Unit 313-315, 3/F Biotech Centre 2
11 Science Park West Avenue
Hong Kong Science Park

US Epitherapeutics
1829 Reisterstown Rd, Suite: 350 Baltimore, MD 21208
+1 (443) 256 5179
MTL Epitherapeutics
600 – 2000 AV McGill College Montreal, QC CA H3A3H3
+1 (514) 448 2185
Shenzhen Lab
Zone E, Floor 4, Building E, Gangzhilong Business Center,
Qinglong Road, Longhua District, Shenzhen

Email Us

info@hkgepitherapeutics.com

Call Us On

Hong Kong: +(852) 60725262 USA: +1 (443) 256 5179 Canada: +1 (514) 448 2185

Founded in 2016 by Prof. Moshe Szyf, a global pioneer in the dynamic and rapidly evolving field of epigenetics, EpiMedTechGlobal (EMTG) stands as a force driving innovation. Officially headquartered in Singapore, our organization directs a state-of-the-art research and diagnostic lab located in Hong Kong, which serves as the epicenter of our groundbreaking endeavors. Here, our dedicated scientists are committed to driving innovation in epigenetics and the early detection of diseases. At EMTG, it’s not just about detecting diseases; it’s about unlocking and offering solutions that promote longevity through the hidden stories in our DNA.

Read More

Useful Links

Recent Posts

©2023, EpiMedTechGlobal. All Rights Reserved.

Follow Us :
Scroll to Top